Compare Revvity Inc (RVTY) vs Vale SA (VALE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Revvity Inc vs Vale SA — how do they compare? Revvity Inc trades at $116.04 (market cap $12.91B), while Vale SA trades at $14.46 (market cap $61.97B). The key difference: Vale SA is far larger — about 4.8× Revvity Inc's market cap, and Vale SA pays the higher dividend (8.35%). Which is the better fit depends on your goals.
| RVTY | VALE | |
|---|---|---|
Market Cap | $12.91B | $61.97B |
Sector | Technology | Basic Materials |
52-Week High | $117.75 | $17.82 |
52-Week Low | $82.26 | $9.71 |
Enterprise Value | $15.23B | $78.22B |
Dividend Yield | 0.24% | 8.35% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RVTY trades at $115.18, down 0.72% on the day, with a bullish technical signal from moving averages and neutral oscillators. The company reported strong Q2 2026 earnings of $1.41 per share, beating estimates, and raised its full-year outlook, driven by diagnostics strength and AI-enabled drug discovery. Revenue for 2025 was $2.86 billion with a net income margin of 8.16%, though valuation ratios like P/E of 55.64 appear elevated. Recent news includes product launches like the SuperFlex prenatal system and presentations at investor conferences.
The outlook is positive with analyst consensus favoring a buy rating and a $120.50 price target, suggesting upside. Key opportunities include robust diagnostics demand and innovation pipelines, while risks involve high valuation multiples and competitive pressures in the healthcare sector. Cash flow improved in 2026 to a net positive $31 million, supporting growth initiatives.
VALE trades at $14.49, down 2.72% with a bearish technical outlook. Recent earnings missed expectations for three consecutive quarters, with Q3 2026 results pending. The company maintains strong cash flow generation ($8.8B operating cash flow in 2025) and a 5.11% net margin, though profitability has declined from 2022 peaks. Analyst consensus is mixed with 38% Buy ratings and a $16.79 price target, representing 16% upside potential.
VALE offers value with reasonable valuations (P/E 28.6, P/B 1.6) and dividend yield, but faces headwinds from rising costs and earnings volatility. The stock's near-term trajectory depends on Q3 earnings delivery and copper segment execution. Key risks include commodity price sensitivity and operational challenges in base metals expansion.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Revvity Inc
Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.
Read more on RVTY →About Vale SA
Vale is the world's largest iron ore miner and one of the largest diversified miners, along with BHP and Rio Tinto. Earnings are dominated by the bulk materials division, primarily iron ore and iron ore pellets, with minor contributions from iron ore proxies, including manganese and coal. The base metals division is much smaller, primarily consisting of nickel mines and smelters with a small contribution from copper.
Read more on VALE →
